



TECHNOLOGY

Use of Novel Sulfonamides to Inhibit the Growth of Prostate Cancer Cells and Tumors

OVERVIEW

According to the American Cancer Society, prostate cancer (PCA) is the most common type of cancer found in American men. Currently, the major therapy for PCA in both primary and advanced stages is androgen deprivation. This treatment exerts its effects on target tissue by either blocking androgen synthesis or preventing binding of androgens to the androgen receptor (AR). However, one of the major downfalls to this method of treatment involves resistance development. The present technology relates to a new class of small molecules and the promise they show as a therapeutic approach to treat PCA by decreasing androgen synthesis and/or androgen receptor expression or function.

APPLICATIONS

-Cancer therapies -Development of novel cancer therapies

ADVANTAGES

-Offers novel approach for the prevention and treatment of PCA. -Involves the use of novel compounds that have therapeutic promise.

STAGE OF DEVELOPMENT

Small molecules possessing anti-cancer properties have been identified.

R&D REQUIRED

Studies are required to demonstrate efficacy and safety prior to use in human subjects.

LICENSING POTENTIAL

UMB seeks partners for commercialization.

CONTACT INFO

Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: ott@umaryland.edu
Phone: (410) 706-2380

Additional Information

INSTITUTION

University of Maryland, Baltimore

PATENT STATUS

U.S. Patent 7,960,435 issued 06/14/2011

LICENSE STATUS

Available for licensing

CATEGORIES

- Therapeutics
- Small molecules

INVESTIGATOR(S)

Vincent C. O. Njar
Puranik Purushottamachar

EXTERNAL RESOURCES

- [First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer..](#)

VN-2007-026